Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir, With or Without Simeprevir, in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Infection With or Without Compensated Child Pugh A Cirrhosis

NCT02569710 is registered in ClinicalTrials.gov with Alios Biopharma Inc. as lead sponsor.

NCT NCT02569710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02569710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir, With or Without Simeprevir, in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Infection With or Without Compensated Child Pugh A Cirrhosis
Lead sponsor
Alios Biopharma Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2015
Completion date
May 11, 2018
Enrollment
161 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c